Sentences with phrase «of angiotensin»

Enhancement of heart muscle contractility and reduction of blood pressure is gained with the use of angiotensin - converting enzyme (ACE) inhibitors such as enalapril and benazepril and vasodilators like amlodipine and diltiazem.

Effects of angiotensin - converting enzyme inhibitors and angiotensin - II type - 1 receptor antagonists in rats with heart failure

They work by inhibiting the conversion of angiotensin I to angiotensin II in the lungs.

Autoregulation of renal blood flow and glomerular filtration rate in neonatal puppies appear to be relatively inefficient in response to rapid changes in systemic arterial blood pressure.7 In adult dogs, the renin — angiotensin system is an important regulatory mechanism; however, in neonates, renal blood flow is directly correlated with arterial pressure and does not seem to be altered by inhibition of angiotensin until approximately 6 weeks of age.

Patients with high urine protein loss may also benefi t from the use of angiotensin converting enzyme (ACE) inhibitors drugs, which will help to slow the progression of disease.

This magical fruit also is found to lower circulating levels of the angiotensin hormone that can help blood vessels to relax.

ACE (angiotensin - converting enzyme)- inhibitors are among the most popular prescription medications prescribed to negate the effect of the angiotensin hormone, and create a life of misery for many due to the myriad of side effects inherent with this class of drug.

Tyrosine is thought to reduce blood pressure by stimulating catecholamine synthesis in the brain (13), whereas histidine has been shown to inhibit vascular expression of the angiotensin converting enzyme mRNA in hypertensive rats (9).

Pert discusses the very real chemistry of gut feelings; of hormones like insulin that act in the brain; and of angiotensin that influences physiology and behavior simultaneously (making you thirsty and allowing your kidneys to hold onto water).

Distinct Pathways for the Trafficking of Angiotensin II and Adrenergic Receptors from the Endoplasmic Reticulum to the Cell Surface.

Rab1 GTPase regulates phenotypic modulation of pulmonary artery smooth muscle cells by mediating the transport of angiotensin II type 1 receptor under hypoxia.

The trafficking protein GABARAP binds to and enhances plasma membrane expression and function of the angiotensin II type 1 receptor.

13 - cis - Retinoic acid specific down - regulation of angiotensin type 1 receptor in rat liver epithelial and aortic smooth muscle cells.

Di - acidic Motifs in the Membrane - distal C Termini Modulate the Transport of Angiotensin II Receptors from the Endoplasmic Reticulum to the Cell Surface.

G protein - coupled receptor kinase and β - arrestin - mediated desensitization of the angiotensin II type 1A receptor elucidated by diacylglycerol dynamics.

C - terminal processing of GABARAP is not required for trafficking of the angiotensin II type 1A receptor.

Interplay between EGR1 and SP1 is critical for 13 - cis retinoic acid - mediated transcriptional repression of angiotensin type 1A receptor.

Abadir and colleagues experimented with gel formulations of angiotensin II receptor antagonists, or blockers, a long - standing class of drugs that includes losartan and valsartan, prescribed to treat hypertension.

Moreover, stimulation of the angiotensin II type 1A receptor activated JNK3 and triggered the colocalization of β - arrestin 2 and active JNK3 to intracellular vesicles.

Angiotensin II significantly improved hypotension (low blood pressure)-- increasing mean arterial pressure at 3 hours — compared with placebo; nearly 70 percent of angiotensin II - treated patients (114 of 163) saw improved blood pressure compared with 23 percent of the placebo group (37 of 158 patients).

This peptide family, which became known collectively as the bradykinin potentiating factor (BPF), was also found to block the conversion of angiotensin I to angiotensin II, a process that causes blood pressure to rise.

The peptides were later used by researchers at Bristol - Myers Squibb to develop the first group of angiotensin - converting enzyme (ACE) inhibitors.

For example, the treatment of hypertension went through several significant changes from the days of the a-adrenoceptor antagonists to that of the latest generation of angiotensin - converting enzyme inhibitors and angiotensin II receptor blockers.

The full data from the Phase III study, dubbed ATHOS - 3, of Angiotensin for treating catecholamine - resistant hypotension, or CRH, was published in the New England Journal of Medicine.

About 69.9 percent of angiotensin II patients achieved the primary endpoint versus 23.4 percent of placebo patients.

Following the publication of full data from a late - stage study of La Jolla Pharmaceutical Company (NASDAQ: LJPC)'s LPJC - 501, a proprietary formulation of angiotensin II, SunTrust Robinson Humphrey said it expects approval in 2018.

Not exact matches

Wang and colleagues published their study in International Journal of Food Science and Technology («Effect of Enzyme Type and Hydrolysis Conditions on the In Vitro Angiotensin I - converting Enzyme Inhibitory Activity and Ash Content of Hydrolyzed Whey Protein Isolate.»

She also isolated and described angiotensin (a hormone that regulates blood pressure), phosphorylase (a critical enzyme involved in conversion of carbohydrates to energy), and serotonin (a molecule involved in many processes, including pain, sleep, and psychological function).

Two classes of blood pressure medications, angiotensin - converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are associated with a 16 % lower risk of strokes, heart attacks and death in patients with end - stage renal disease who are undergoing peritoneal dialysis, a new study in the journal, Nephrology Dialysis Transplantation, reports.

«Unexpectedly, FGF21 works through a new pathway that is independent of the classical renin - angiotensin - aldosterone thirst pathway in the kidneys.»

It is the first and largest phase III randomized controlled trial of stable, synthetic human angiotensin II.

The study enrolled 321 patients — 163 treated with angiotensin II and 158 with placebo — who were experiencing vasodilatory shock and had received high doses of conventional vasopressors.

Current therapies include surgery, for example replacing the weakened part of the aorta, and medical treatments such as beta - blockers or angiotensin receptor blockers.

Mads E. Jørgensen, M.B., of Gentofte Hospital, University of Copenhagen, Denmark and coauthors examined in - hospital records and out - of - hospital pharmacotherapy use in Danish patients with uncomplicated hypertension treated with at least two antihypertensive drugs (β - blockers, thiazides, calcium antagonists or renin - angiotensin system [RAS] inhibitors) undergoing noncardiac surgery between 2005 and 2011.

Results of a new study led by Johns Hopkins researchers offer new evidence for a strong link between angiotensin receptor autoantibodies and increased risk of frailty.

«Building off of our knowledge that these autoantibodies cause chronic inflammation, we decided to look at a class of medications, angiotensin receptor blockers, that block inflammation and are commonly prescribed to lower blood pressure,» says Peter M. Abadir, M.D., associate professor of medicine at the Johns Hopkins University School of Medicine and the paper's lead author.

«We discovered that frail older individuals have markedly higher levels of an autoantibody against its own angiotensin system.

Agents called renin - angiotensin - system (RAS) inhibitors can reduce both of these; however, patients» risk of experiencing residual albuminuria remains high.

Using 2006 - 11 data from Medicare's Part D drug benefit, the study found that 60 percent of patients with heart problems who saw a cardiologist received ACE inhibitors or angiotensin receptor blockers, versus 44 percent of those who didn't see a cardiologist.

Objective To determine whether treatment with a calcium channel blocker or an angiotensin - converting enzyme inhibitor lowers the incidence of coronary heart disease (CHD) or other cardiovascular disease (CVD) events vs treatment with a diuretic.

Symposia and poster abstracts will focus on reactive oxidant stress, nitric oxide, angiotensin II, angiotensin (1 - 7), glutamate, GABA and the transcriptional and translational regulation of the receptors for many of these mediators.

Molecular characterization of new selective peroxisome proliferator - activated receptor gamma modulators with angiotensin receptor blocking activity.

Angiotensin II signalling and calcineurin in cardiac fibroblasts: differential effects of calcineurin inhibitors FK506 and cyclosporine A. Therapeutic Advances in Cardiovascular Disease, 6 (1), 5 — 14.

Antenatal maternal protein deprivation: sexually dimorphic programming of the pancreatic renin - angiotensin system.

Regulation of anterograde transport of adrenergic and angiotensin II receptors by Rab2 and Rab6 GTPases.

Typically, angiotensins have been linked to blood pressure regulation, but Harding and Wright noticed that angiotensin IV, or early drug candidates based on it, were capable of reversing learning deficits seen in many models of dementia.

Endoplasmic reticulum export of adrenergic and angiotensin II receptors is differentially regulated by Sar1 GTPase.

Angiotensin II receptor type 1 (Agtr1a): Lowering Agtr1a protein levels protects mitochondrial function and modestly extends life in mice, though as for many of these methods of somewhat slowing aging there are probably many other changes to the operation of metabolism that are as yet unexplored.

Mechanisms of Dopamine D1 and Angiotensin Type 2 Receptor Interaction in Natriuresis.

Facilitation of Hippocampal Synaptogenesis and Spatial Memory by C - Terminal Truncated Nle1 - Angiotensin IV Analogs.